Tax on salt could reduce cardiovascular disease deaths by 3 percent
Voluntary industry reductions in salt content and taxation on products containing salt in 19 developing countries could reduce the number of deaths each year from cardiovascular disease (CVD) by 2-3 per cent in these countries. The preliminary data presented today at the World Congress of Cardiology are the first findings from a new report from Harvard that will be published later this year.
The study set out to assess the cost-effectiveness of two interventions - voluntary salt reduction by industry, and taxation on salt - in 19 developing countries, that represent more than half of the world's population. The required salt reduction levels were modeled on the UK Food Standards Agency experience which set a series of targets for individual food products that have led to a net intake reduction, so far, of 9.5 per cent overall in the country. While a taxation increase of 40 per cent on industry prices (similar to tobacco), determined by previous work to lead to a 6 per cent reduction in consumption, was also evaluated.
The analysis found that both strategies would be save money by reducing the number of people needing treatment for hypertension and CVD events such as myocardial infarction (heart attacks) and stroke. Moreover, the study found that these two strategies could reduce the incidence of myocardial infarctions (heart attacks) by up to about 1.7 per cent and 1.47 per cent in China and India respectively. Reductions would also been seen in the incidence of stroke of 4.7 per cent in China and 4 per cent in India.
"These results show that strategies to reduce sodium consumption, even by modest amounts, could lead to significant reductions in CVD mortality in developing countries and potentially save overall healthcare costs associated with these diseases," said Dr. Thomas Gaziano, assistant professor, Harvard School of Medicine. "In developing countries, where the burden of CVD is highest, these simple steps could deliver a significant long-term impact and must be something that governments trying to manage rising healthcare costs should consider."
CVD is the world's biggest killer, claiming 17.3 million lives each year. More than 80 per cent of CVD deaths occur in low- and middle-income countries. Projections suggest that CVD will remain the single leading cause of death, and by 2030 will be responsible for 23.6 million deaths each year.
Salt intake and cardiovascular disease
Elevated sodium intake has significant implications for cardiovascular health. A positive relationship between salt intake and high blood pressure has been established, while salt reduction trials have revealed that a decrease in salt intake is directly related to a decrease in blood pressure.
Hypertension (high blood pressure) is one of the major preventable risk factors for premature death from CVD worldwide. High blood pressure contributes to around half of all CVD and the risk of developing CVD doubles for every 10-point increase in diastolic blood pressure.
High blood pressure that is left untreated can greatly increase a person's risk of developing CVD. Treating raised blood pressure has been associated with a 35-40 per cent reduction in the risk of stroke and at least a 16 per cent reduction in the risk of myocardial infarction.
Provided by World Heart Federation
-
Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Apr 22, 2012 |
not rated yet |
0
-
Exercise reduces risk of death from cardiovascular disease in people with high blood pressure
Apr 19, 2012 |
not rated yet |
0
-
Cardiovascular disease risk of high normal blood pressure decreases in old age
Apr 20, 2012 |
not rated yet |
0
-
Study evaluates relationship of urinary sodium with health outcomes
May 03, 2011 |
not rated yet |
0
-
Largest-ever risk factor study in India identifies cardiovascular disease epidemic causes
Apr 20, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Normal force for a lever model
1 hour ago
-
gravity is std. therefore can we rate a 'mass at height' by watts?
6 hours ago
-
Calculating on-axis elements of a solenoid
18 hours ago
-
latitude & longitude & air pressure
19 hours ago
-
Differences of Classical Mechanics when learned with Calc vs algebra?
22 hours ago
-
what is the distance traveled
May 22, 2013
- More from Physics Forums - Classical Physics
More news stories
Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
Cardiology
4 hours ago |
not rated yet |
0
Costs to treat stroke in America may double by 2030
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology
May 22, 2013 |
not rated yet |
0
New blood-thinner measures may cut medication errors
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology
May 22, 2013 |
not rated yet |
0
Registry questions superiority of bivalirudin over heparin
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology
May 22, 2013 |
5 / 5 (1) |
0
Study shows low rate of late lumen loss with bioresorbable DESolve device
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...
Cardiology
May 22, 2013 |
not rated yet |
0
Ferrets, pigs susceptible to H7N9 avian influenza virus
Chinese and U.S. scientists have used virus isolated from a person who died from H7N9 avian influenza infection to determine whether the virus could infect and be transmitted between ferrets. Ferrets are often used as a mammalian ...
Scientists discover molecule triggers sensation of itch
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as the sensation of ...
Multiple research teams unable to confirm high-profile Alzheimer's study
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Motion quotient: IQ predicted by ability to filter motion (w/ video)
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
Researchers find common childhood asthma unconnected to allergens or inflammation
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
Drug reverses Alzheimer's disease deficits in mice, research confirms
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.